New Jersey-based Savient Pharmaceuticals signed a deal to supply the U.S. Department of Veterans Affairs with Krystexxa, its new gout drug, along with its weight-gain medication, Oxandrin, for five years, according to Fierce Pharma.

Krystexxa won FDA approval last September as a treatment for severe gout. Savient had hoped to sell itself quickly but failed to find a buyer, according to Fierce Pharma. The company has been working to build a U.S. sales force.